Back

Dual or single anti-thrombotic therapy in patients with atrial fibrillation after TAVI: a pre-specified analysis from the ENVISAGE-TAVI AF trial

20 February 2026 (09:45 - 10:30)
Organised by: Logo
Congress Presentation Part of: Poster session (2) - Pharmacology and pharmacotherapy Antiplatelet Drugs EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Professor Marco Valgimigli

Cardiocentro Ticino Institute, Lugano (Switzerland)

4 More presentations in this session

Presentation thumbnail
Doctor A. Laino (Naples, IT)
Abstract Slides
Presentation thumbnail
Doctor A. Emara (Menoufia, EG)
Abstract
Presentation thumbnail
Mr J. Rogozarski (Vienna, AT)
Abstract Slides
Presentation thumbnail

Access the full session

Session thumbnail
Poster session (2) - Pharmacology and pharmacotherapy

The Event

Event poster

EAPCI Summit 2026

20 February 2026 09:45 CET
You may be interested in
thumbnail
Congress Presentation
Single versus dual antiplatelet therapy following transcatheter left atrial appendage closure
4 April 2022
thumbnail
Congress Presentation
Evaluation of new-onset atrial fibrillation using continuous patch monitor in patients undergoing transcatheter aortic valve replacement
28 August 2020
thumbnail
Congress Presentation
Temporal trends in antithrombotic therapy following transcatheter aortic valve implantation in denmark
30 August 2024
thumbnail
Congress Presentation
Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry.
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources